Ainos Enters Material Agreement for Stock & Warrants Issuance
Ticker: AIMDW · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1014763
| Field | Detail |
|---|---|
| Company | Ainos, INC. (AIMDW) |
| Form Type | 8-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $5 million, $161,000, $95,000 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: capital-raise, equity-offering, warrants, dilution
TL;DR
**Ainos just issued new stock and warrants, likely raising cash but potentially diluting current shares.**
AI Summary
Ainos, Inc. entered into a material definitive agreement on January 8, 2024, for the issuance of common stock and warrants. This filing indicates a potential capital raise for the company, which could dilute existing shareholders if the warrants are exercised, but also provides funding for operations. Investors should note this could impact the stock's value due to increased share count.
Why It Matters
This agreement suggests Ainos is raising capital, which can fund growth but may dilute existing shareholders if new shares and warrants are exercised, potentially impacting stock price.
Risk Assessment
Risk Level: medium — The issuance of new shares and warrants carries a medium risk of dilution for existing shareholders, potentially impacting the stock price negatively.
Analyst Insight
A smart investor would monitor the details of the material definitive agreement, once disclosed, to understand the extent of potential dilution and the use of proceeds, before making any investment decisions.
Key Players & Entities
- Ainos, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported and the material definitive agreement
Forward-Looking Statements
- Ainos, Inc. will experience short-term stock price volatility due to potential dilution from the issuance of common stock and warrants. (Ainos, Inc.) — medium confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 8, 2024, when Ainos, Inc. entered into a material definitive agreement.
What type of agreement did Ainos, Inc. enter into on January 8, 2024?
Ainos, Inc. entered into a material definitive agreement for the issuance of common stock and warrants on January 8, 2024.
What is the Central Index Key (CIK) for Ainos, Inc.?
The Central Index Key (CIK) for Ainos, Inc. is 0001014763.
What is the business address of Ainos, Inc.?
The business address of Ainos, Inc. is 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108.
What was the former name of Ainos, Inc. and when did the name change occur?
The former name of Ainos, Inc. was AMARILLO BIOSCIENCES INC, and the name change occurred on May 16, 1996 (19960516).
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-01-12 16:12:12
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share AIMD The Nasdaq Stock Mar
- $5 million — . The Company will pay a total fee of NT$5 million (approximately USD$161,000) for five-ye
- $161,000 — l fee of NT$5 million (approximately USD$161,000) for five-years of development commenci
- $95,000 — OCT technologies for a monthly fee of US$95,000 (plus 5% sales tax), with negotiable pa
Filing Documents
- aimd_8k.htm (8-K) — 29KB
- aimd_ex101.htm (EX-10.1) — 34KB
- aimd_ex102.htm (EX-10.2) — 16KB
- 0001654954-24-000521.txt ( ) — 225KB
- aimd-20240108.xsd (EX-101.SCH) — 6KB
- aimd-20240108_lab.xml (EX-101.LAB) — 16KB
- aimd-20240108_cal.xml (EX-101.CAL) — 1KB
- aimd-20240108_pre.xml (EX-101.PRE) — 12KB
- aimd-20240108_def.xml (EX-101.DEF) — 4KB
- aimd_8k_htm.xml (XML) — 5KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On August 1, 2021, Ainos, Inc. ( the "Company") entered into a five-year Product Development Agreement (the "Original Agreement") with Taiwan Carbon Nano Technology Corporation ("TCNT"), an affiliate company. Pursuant to the Original Agreement, the parties will co-develop pharmaceutical, medical device and other products defined in the agreement. On January 9, 2024, the Company and TCNT entered into an addendum to the Product Development Agreement ("Addendum Agreement") in connection with the scope of co-development and certain terms. For products defined in the Addendum agreement, TCNT will provide facilities, equipment, mass production process technology, ISO9001 and ISO13485 related management, as well as mass production support. The procurement of parts and raw materials, rental fees, and utility expenses are excluded. The Company will pay a total fee of NT$5 million (approximately USD$161,000) for five-years of development commencing from 2024. For six months commencing from January 2024, TCNT will provide non-exclusive use of certain patents related to VOC and POCT technologies for a monthly fee of US$95,000 (plus 5% sales tax), with negotiable payment terms. The parties can discuss subsequent use of the patents at later dates. The Company's audit committee ratified the Original Agreement and approved the Addendum Agreement on January 8, 2024.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibits 10.1 English Translation of Product Development Agreement, dated on August 1, 2021 10.2 English Translation of Addendum to the Product Development Agreement, dated on January 9, 2024 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ainos, Inc. Date: January 12, 2024 By: /s/ Chun-Hsien Tsai Name: Chun-Hsien Tsai Title: Chief Executive Officer 3